The use of hematological effects in the development of minimal risk levels

Area of Science:

• Environmental Health Sciences
• Toxicology
• Hematology

Background:

• The Agency for Toxic Substances and Disease Registry (ATSDR) develops minimal risk levels (MRLs) to evaluate health risks associated with hazardous substance exposure.
• MRLs are derived from the most sensitive health endpoints identified in human or animal studies, specifically no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs).
• Hematological endpoints are frequently utilized in MRL derivation due to their sensitivity to toxicant exposure.

Purpose of the Study:

• To provide an overview of the hematological system and its relevant endpoints in toxicology.
• To illustrate the application of hematological data in deriving minimal risk levels (MRLs) for hazardous substances.
• To present existing MRLs for substances where hematological endpoints were the most sensitive indicators of toxicity.

Main Methods:

• Review of published scientific literature to identify studies with hematological endpoints.
• Selection of the most sensitive hematological endpoints (NOAELs/LOAELs) for MRL derivation.
• Calculation of inhalation and oral MRLs based on identified sensitive hematological data for various substances.

Main Results:

• To date, 4 inhalation MRLs and 13 oral MRLs have been derived using hematological endpoints for 12 different substances.
• The paper includes examples of specific hematological endpoints and the corresponding MRLs.
• The findings highlight the importance of hematology in assessing risks from environmental toxicants.

Conclusions:

• Hematological endpoints are critical for establishing reliable minimal risk levels (MRLs) for hazardous substances.
• The ATSDR's MRLs derived from hematological data provide valuable guidance for risk assessment and public health protection.
• Further research may expand the number of MRLs based on hematological data for a wider range of substances.